1 active not recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Dosage Forms: new trials by email Literature Review of Dosage Forms trials Research Report on Dosage Forms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN Selumetinib granule formulation, Selumetinib capsule formulation - Neurofibromatosis Type 1 | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 36 | 2022-01-21 | 2026-08-13 |
AstraZeneca (1)
Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Russia (1) · Spain (1) · United States (1)